Bristol Myers Squibb Access Support and Cell Therapy 360
Bristol Myers Squibb (BMS) offers the Access Support and Cell Therapy 360 programs for patients prescribed a BMS medication. These programs help provide eligible patients access to BMS oncology medications and patient support services. The support offered varies based on the patient’s prescribed medication and insurance status. See the Table for a list of oncology and oncology supportive drugs, drug indications, and program information.
BMS Access Support
BMS Oncology Co-Pay Assistance Program
Access to certain BMS oncology products is supported through the BMS Oncology Co-Pay Assistance Program. This program is designed for commercially insured patients who need financial assistance with out-of-pocket deductibles, copays, or coinsurance.
BMS Patient Assistance Foundation
For patients who have government insurance, are underinsured, or have no prescription drug insurance, BMS Access Support can make a referral to independent charitable foundations. Each foundation has its own eligibility criteria and evaluation process. BMS cannot guarantee that a patient will receive assistance.
The BMS Patient Assistance Foundation (BMSPAF) may provide medicine, free of charge, to eligible, uninsured patients who have an established financial hardship.
Cell Therapy 360 Program
For patients on a BMS CAR T-cell therapy (Abecma or Breyanzi), Cell Therapy 360 provides access and reimbursement support, 24/7 on-call assistance, and a Scheduling and Apheresis Portal.
Through the Cell Therapy 360 Copay Program, patients with commercial insurance can receive up reimbursement for out-of-pocket costs covered for their CAR T-cell therapy.
Cell Therapy 360 may be able to enable access to CAR T-cell therapy for your uninsured patients or for those patients whose insurance excludes coverage for CAR T-cell therapy and have financial need.
Patients enrolled in the Cell Therapy 360 program can also receive posttreatment monitoring assistance as well as 24/7 access to a field medical director with CAR T-cell therapy clinical experience.
TABLE BMS Oncology Drugs
Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion Indications
- refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
- refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age; or
- relapsed or refractory disease after 2 or more lines of systemic therapy
Opdivo (nivolumab) Indications
Neoadjuvant treatment of adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy; in combination with ipilimumab, for first-line treatment of metastatic NSCLC in adult patients whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test with no EGFR or ALK genomic tumor aberrations; treatment of adult patients in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy as first-line treatment of metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations; treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo.
First-line treatment of adult patients with unresectable malignant pleural mesothelioma in combination with ipilimumab.
First-line treatment of adult patients with intermediate or poor-risk advanced renal-cell carcinoma (RCC) in combination with ipilimumab; first-line treatment of adult patients with advanced RCC in combination with cabozantinib; treatment of adult patients with advanced RCC who have received prior antiangiogenic therapy.
Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after either autologous HSCT and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous HSCT.
Treatment of adult patients with recurrent or metastatic squamous-cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.
Adjuvant treatment of adult patients with urothelial carcinoma who are at high risk for recurrence after undergoing radical resection; treatment of adult patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Treatment of adult and pediatric (12 years and older) patients, administered as a single agent or in combination with ipilimumab, with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenibin combination with ipilimumab.
Adjuvant treatment of adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy; treatment of adults with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma after prior fluoropyrimidine- and platinum-containing chemotherapy.
Treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Pomalyst (pomalidomide) Indications
Reblozyl (luspatercept-aamt) Indications
- anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions
- anemia in adult patients without previous erythropoiesis-stimulating agent use and with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular RBC transfusions
- anemia in adult patients who responded inadequately to an erythropoiesis-stimulating agent and requiring 2 or more RBC units over 8 weeks and with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Revlimid (lenalidomide) capsules Indications
multiple myeloma, in combination with dexamethasone or as maintenance after autologous hematopoietic stem-cell transplant; transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q; mantle-cell lymphoma in patients whose disease relapsed or progressed after 2 therapies, including bortezomib; previously treated follicular lymphoma, in combination with rituximab-containing therapy; previously treated marginal-zone lymphoma, in combination with rituximab-containing therapy
Sprycel (dasatinib) Indications
- newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
- adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib
- adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy
- pediatric patients 1 year of age and older with Ph+ CML in chronic phase
- pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy